What Researchers Did
Researchers conducted a narrative review of the literature on neuroblastoma, focusing on hyperbaric oxygen therapy (HBOT) as a complementary treatment.
What They Found
The review detailed neuroblastoma's pathophysiology, clinical presentation, and diverse biological and genetic profiles, noting it is the most frequently diagnosed cancer in the first year of life.
It explored current multimodal therapy approaches and discussed hyperbaric oxygen therapy (HBOT) as a proposed complementary measure to address tumor hypoxia, a key factor in treatment resistance.
What This Means for Canadian Patients
For Canadian patients with neuroblastoma, this review suggests that hyperbaric oxygen therapy (HBOT) could be a potential complementary treatment to improve outcomes by addressing tumor hypoxia.
Patients and their healthcare providers might consider discussing the role of HBOT within their comprehensive treatment plans.
Canadian Relevance
This narrative review does not have a direct Canadian connection.
Study Limitations
As a narrative review, this study's findings are based on a subjective synthesis of existing literature and may not encompass all relevant evidence or critically appraise its quality.